A day af­ter Mod­er­na vac­cine re­sults, ru­mors swirl of pend­ing As­traZeneca da­ta

A day af­ter Mod­er­na and the NIH pub­lished much-an­tic­i­pat­ed da­ta from their Phase I Covid-19 vac­cine tri­al, at­ten­tion is turn­ing to As­traZeneca which, ac­cord­ing to a UK re­port, is ex­pect­ed to pub­lish its own ear­ly da­ta to­mor­row.

ITV’s Robert Pe­ston re­port­ed that As­traZeneca will pub­lish the Phase I da­ta in The Lancet. 

As­traZeneca and Mod­er­na rep­re­sent the two most am­bi­tious Covid-19 vac­cine ef­forts, hav­ing set the quick­est time­lines for ap­proval (though they were re­cent­ly joined in that re­gard by the Pfiz­er-BioN­Tech part­ner­ship) and some of the lofti­est goals in to­tal dos­es. Yet there is even less known about As­traZeneca’s vac­cine’s ef­fect on hu­mans than there was about Mod­er­na’s be­fore yes­ter­day. Al­though, in a con­tro­ver­sial move, Mod­er­na re­leased some sta­tis­tics from its Phase I in May, As­traZeneca has yet to say any­thing about what it saw in its Phase I tri­al — a move con­sis­tent with the sci­en­tif­ic con­ven­tion to with­hold da­ta un­til it can be pub­lished in a peer-re­viewed jour­nal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER